Indivior PLC (INVVY)
Indivior PLC operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in North Chesterfield, VA, US. The stock last traded at $21.85, up 0.00% on the session, giving a market capitalisation of $3.01B. On trailing twelve-month figures it carries a trailing P/E of 13.50, a net margin of 26.7%. Its beta of -0.06 implies it has historically moved less than the broad market.
Indivior PLC, encompassing its various subsidiaries, is a pharmaceutical firm dedicated to the research, production, and global commercialization of prescription medications. These therapies primarily utilize buprenorphine to treat opioid dependence and associated medical conditions. The company's development pipeline is actively exploring novel treatments for opioid use disorder (OUD) and schizophrenia. Its current portfolio features the SUBLOCADE subcutaneous injection, along with sublingual formulations like SUBOXONE film, SUBOXONE tablets, and SUBUTEX tablets. Additionally, Indivior sells established products such as Temgesic, Burpex, and Buprenex. With operations spanning approximately 40 countries worldwide, the company also maintains a research collaboration agreement with Addex Therapeutics Ltd. Indivior PLC was founded in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior PLC is most often compared with the following Healthcare names: